Home › Companies › TTRX

Turn Therapeutics Inc.

TTRX Lead: Phase 2 4 Biotech Distilled articles ↓

Most recent annual filing: 2026-03-31

Pipeline (4 active programs)

GX-03

Small Molecule Target: IL-31, IL-36α, IL-36γ, IL-4, IL-36α/γ

Moderate-to-Severe Eczema Phase 2 topical
Onychomycosis Preclinical topical
Atopic Dermatitis Phase 2 topical

intranasal influenza vaccine

Influenza nasal

Technology platforms

PermaFusion · Medline

PermaFusion is an oil-based suspension delivery platform enabling uniform delivery of water-soluble actives without emulsifiers; applications include thermostable intranasal live vaccine stabilization and dermatologic/antifungal product formulations. Focus areas include vaccines and dermatology.

PermaFusion

Proprietary platform technology designed to enhance drug performance; primary focus on dermatological diseases including atopic dermatitis and onychomycosis; also underlies FDA-cleared medical device portfolio.

Biotech Distilled coverage (4)

2026-05-18 UPDATE: Turn Therapeutics (TTRX) - A Former FDA Commissioner Walks Into a Pre-Readout Small-Cap 🔒 Paid
2026-05-12 UPDATE: Turn Therapeutics (TTRX) - The Interim Clock Just Moved Up 🔒 Paid
2026-03-28 UPDATE: Turn Therapeutics (TTRX) - TTRX Buys Time with a $25M Lifeline... 🔒 Paid
2026-03-19 Turn Therapeutics (TTRX) - Scientific Deep Dive for GX-03 and Pipeline Products 🔒 Paid

Articles open on Substack. Some deep dives are subscriber-only.